Building Towards A Greener Future By Implementing Sustainable Manufacturing Practices

Amid huge strides towards developing innovative and effective therapeutics for patients across the pharmaceutical fine chemicals (PFC) industry, drug developers and CDMOs are increasingly adapting their manufacturing processes to be sustainable and eco-conscious. Due to the complexity of chemical synthesis of pharmaceuticals and the high amount of waste produced, the carbon footprint and waste-to-product ratio in PFC is among the highest in the chemical industry. To combat this, CDMOs are assessing where green innovation can be applied.

In a recent webinar hosted by Ajinomoto Bio-Pharma Services, Geert Schelkens, R&D Manager Early Phase API, and Peggy De Clercq, Key Account Manager, discussed different process adaptations to build greener, more sustainable workflows in drug development. The experts provided their insight into how manufacturers are leveraging renewable raw material sources, green chemistry strategies, and innovative technologies. Download the full article to explore Schelkens’ insight into attendee questions on continuous manufacturing, aqueous chemistry, and reducing biopharma’s carbon footprint via process development.